ER 100
Alternative Names: ER-100Latest Information Update: 03 Feb 2026
At a glance
- Originator Harvard University
- Developer Life Biosciences
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ischaemic optic neuropathy; Open-angle glaucoma
Most Recent Events
- 29 Jan 2026 US FDA approves IND application for ER 100 in Non-arteritic anterior ischaemic optic neuropathy (NAION) and open angle glaucoma
- 22 Jul 2025 Life Biosciences plans clinical trial for ER 100 for glaucoma and non-arteritic anterior ischaemic optic neuropathy in the first quarter of 2026 (NCT07290244)
- 21 Oct 2024 Pharmacodynamics data from a preclinical trials in Ischaemic optic neuropathy released by Life Biosciences